Moffitt Cancer Center | Strategic Alliance Partners

An oncology nurse and pharmacist discuss the multidisciplinary approach to administering TIL therapy in patients with advanced melanoma.

An expert discussed how the benefits of mindfulness in patients with cancer can also be applied to oncology nurses.

Two experts commented on ways oncology nurses can learn more about administering TIL therapy and how they can play a supportive role for patients receiving the treatment.

Virtual reality headsets can be used to reduce anxiety in patients with cancer undergoing treatment and as an educational tool for nurses learning how to have difficult conversations with patients.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.

Amy Martinez, BSN, RN, OCN, explains how her team incorporated the Timed-Up-and-Go test into their workflows on a radiology unit.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Pure essential oils reduced the severity of chemotherapy-induced nausea and vomiting in patients receiving autologous blood and marrow transplants.

Although most patients in the real-world setting would not have met the clinical trial eligibility criteria, the efficacy and safety outcomes with idecabtagene vicleucel were similar for both sets of patients with multiple myeloma.

Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.

Brexucabtagene autoleucel, a CAR T-cell therapy approved in 2021 for relapsed or refractory B-cell acute lymphoblastic leukemia, showed efficacious results and promising safety data at 2-year follow-up.

Approval of off-the-shelf CAR T-Cell therapy options would provide greater accessibility and benefit to patients, say experts.

Pilot programs based out of Yale Cancer Center and Moffitt Cancer Center seek to improve access for newly diagnosed patients with cancer.

Investigators are seeking to overcome barriers to help patients with acute myeloid leukemia achieve complete and durable remissions by focusing their attention on novel agents engineered to target adhesion factors.

Investigators hope that the novel obecabtagene autoleucel, a second-generation CAR T-cell therapy may fill an unmet need by representing a durable treatment option for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

Mark Honor, PA-C, highlights best adverse event management practices for patients undergoing chemotherapy and immune-based treatment.

Patients with cancer should receive the entire COVID-19 vaccination as soon as possible, according to an expert at the 39th Annual Chemotherapy Foundation Symposium.

Kelly Garvin, BSN, RN, OCN, discusses the impact of CAR T-cell therapy on patients and how nurses care for them, as well as her expectations on how indications will grow.

Kelly L. Garvin, BSN, RN, OCN, discusses what changes she hopes to see in CAR T-Cell therapy treatment over the coming years.

Although the use of CAR T-cell therapies are associated with potentially serious adverse events, the treatment provides patients whose disease has failed to respond to previous treatments with hope, according to Kelly Garvin, BSN, RN, OCN.

Data from a 5-year follow-up study confirmed that CPX-351 continues to be associated with long-term remission and improved overall survival compared to 7+3 chemotherapy in certain older patients with acute myeloid leukemia.

A virtual presentation at the 2021 American Society of Clinical Oncology Annual Meeting suggested that patients with B-ALL benefit from single infusions of KTE-X19 (Tecartus).

Nurses need to know the potentially life-threatening adverse events of CAR T-cell therapy.

Robert M. Wenham, MD discusses evolving strategies in the ovarian cancer space.